参考文献/References:
[1] 中国心血管健康与疾病报告编写组中国心血管健康与疾病报告2022概要[J]. 中国循环杂志,2023,38(6):583-612.
[2] Carr SS,Hooper AJ,Sullivan DR,et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment [J]. Pathology,2019,51(2):148-54.
[3] 王增武,刘静,李建军,. 中国血脂管理指南（2023年）[J]. 中国循环杂志,2023,38(3):237-71.
[4] Hoogeveen RC,Ballantyne CM. Residual cardiovascular risk at low LDL:remnants,lipoprotein(a),and inflammation[J]. Clin Chem,2021,67(1):143-153.
[5] 彭及雅,李欣颖,张大庆. LDL-C、non-HDL-C和ApoB100的临床应用价值评价[J]. 临床检验杂志,2021,39(7):521-4.
[6] 杨阳,彭道泉. 非高密度脂蛋白胆固醇作为降脂治疗目标的意义[J]. 中华检验医学杂志,2021,44(7):569-73.
[7] Soppert J,Lehrke M,Marx N,et al. Lipoproteins and lipids in cardiovascular disease:from mechanistic insights to therapeutic targeting[J]. Adv Drug Deliv Rev,2020,159:4-33.
[8] Borén J,Chapman MJ,Krauss RM,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2020,41(24):2313-2330.
[9] 张丽沙,吴寿岭,邵郅强,. 非高密度脂蛋白胆固醇对绝经后女性心血管疾病的影响[J]. 中国循环杂志,2024,39(1):61-7.
[10] 中华医学会检验医学分会,中国医师协会检验医师分会,中国生物化学与分子生物学会脂质与脂蛋白专业委员会,. 中国临床血脂检测指南[J]. 中华检验医学杂志,2022, 45(10):1017-33.
[11] Wu F,Juonala M,Jacobs DR Jr,et al. Childhood non-HDL cholesterol and LDL cholesterol and adult atherosclerotic cardiovascular events[J]. Circulation,2024,149(3):217-226.
[12] Johannesen CDL,Mortensen MB,Langsted A,et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated?patients[J]. J Am Coll Cardiol,2021,77(11):1439-1450.
[13] Hong S,Han K,Park JH,et al. Higher non-high-density lipoprotein cholesterol was higher associated with cardiovascular disease comparing higher LDL-C in nine years follow up:cohort study[J]. J Lipid Atheroscler,2023,12(2):164-174.
[14] Zheng Q,Wang H,Wang X,et al. Individual and combined contributions of non-high-density lipoprotein cholesterol and brachial-ankle pulse wave velocity to cardiovascular disease risk:results of a prospective study using the Kailuan cohort[J]. Front Cardiovasc Med,2023,10:1105464.
[15] Guan XM,Shi HP,Xu S,et al. Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease:a prospective community-based study[J]. Front Cardiovasc Med,2023,10:1105342.
[16] Pencina KM,Thanassoulis G,Wilkins JT,et al. Trajectories of non-HDL cholesterol across midlife:implications for cardiovascular?prevention[J]. J Am Coll Cardiol,2019,74(1):70-79.
[17] Brunner FJ,Waldeyer C,Ojeda F,et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification:results from the Multinational Cardiovascular Risk Consortium[J]. Lancet,2019,394(10215):2173-2183.
[18] Su X,Kong Y,Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol[J]. Lipids Health Dis,2019,18(1):134.
[19] Kathariya G,Aggarwal J,Garg P,et al. Is evaluation of non-HDL-C better than calculated LDL-C in CAD patients? MMIMSR experiences[J]. Indian Heart J,2020,72(3):189-191.
[20] Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
[21] Wang J,Miao R,Chen Z,et al. Age-specific association between non-HDL-C and arterial stiffness in the Chinese population[J]. Front Cardiovasc Med,2022,9:981028.
[22] Wen J,Huang Y,Lu Y,et al. Associations of non-high-density lipoprotein cholesterol,triglycerides and the total cholesterol/HDL-C ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population[J]. Hypertens Res,2019,42(8):1223-1230.
[23] Jia X,Qi Y,Zheng R,et al. Discordance of apolipoprotein B,non-HDL-cholesterol,and LDL-cholesterol predicts risk of increased arterial stiffness and elevated carotid intima-media thickness in middle-aged and elderly Chinese adults[J]. Front Cardiovasc Med,2022,9:906396.
[24] Bj?rnsson E,Thorleifsson G,Helgadóttir A,et al. Association of genetically predicted lipid levels with the extent of coronary atherosclerosis in Icelandic adults[J]. JAMA Cardiol,2020,5(1):13-20.
[25] Chen S,Cheng W. Relationship between lipid profiles and hypertension:a cross-sectional study of 62,957 Chinese adult males[J]. Front Public Health,2022,10:895499.
[26] Cheng W,Zhuang J,Chen S. Dyslipidemia and the prevalence of hypertension:a cross-sectional study based on Chinese adults without type 2 diabetes mellitus[J]. Front Cardiovasc Med,2022,9:938363.
[27] Alé MC,Echeverría G,Jugo A,et al. [Non-HDL cholesterol levels in Chilean population and their association with diabetes mellitus and cardiovascular disease][J]. Rev Med Chil,2019,147(11):1365-1373.
[28] Yang T,Liu Y,Li L,et al. Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary heart disease:a RCSCD-TCM study in China[J]. Cardiovasc Diabetol,2022,21(1):93.
[29] He Y,Chiang C,Gebremariam LW,et al. Factors associated with prediabetes and diabetes among public employees in northern Ethiopia[J]. Asia Pac J Public Health,2021,33(2/3):242-250.
[30] Tian X,Zuo Y,Chen S,et al. Association of changes in lipids with risk of myocardial infarction among people without lipid-lowering therapy[J]. Atherosclerosis,2020,301:69-78.
[31] Hansen MK,Mortensen MB,Warnakula Olesen KK,et al. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol:a cohort study[J]. Lancet Reg Health Eur,2024,36:100774.
[32] Li TY,Zhu P,Song Y,et al. Discordance analysis for apolipoprotein and lipid measures for predicting myocardial infarction in statin-treated patients with coronary artery disease:a cohort study[J]. J Geriatr Cardiol,2023,20(12):845-854.
[33] Wongcharoen W,Sutthiwutthichai S,Gunaparn S,et al. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol?:a retrospective study[J]. BMC Cardiovasc Disord,2017,17(1):10.
[34] Sivri F,?ztürk Ceyhan B. Increased plasma non-high-density lipoprotein levels and poor coronary collateral circulation in patients with stable coronary artery disease[J]. Tex Heart Inst J,2023,50(3):e227934.
[35] Li C,He K,Yang Y,et al. Nomograms based on non-high-density lipoprotein to predict outcomes in patients with prior coronary artery bypass grafting with acute coronary syndrome:a single-center retrospective study[J]. Ther Clin Risk Manag,2023,19:15-26.
[36] Kanda D,Miyata M,Ikeda Y,et al. The priority of non-HDL-C assessment to predict new lesions among stable angina patients with strong statins[J]. J Atheroscler Thromb,2022,29(6):894-905.
相似文献/References:
[1]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(9):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[2]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(9):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[3]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(9):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[4]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(9):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[5]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(9):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[6]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[7]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[8]安海英 涂建成.载脂蛋白B与非高密度脂蛋白胆固醇在ASCVD防控中的应用价值[J].心血管病学进展,2022,(9):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
AN Haiying,TU Jiancheng.Application Value of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol in ASCVD Prevention and Control[J].Advances in Cardiovascular Diseases,2022,(9):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
[9]黄橙 李波 李志勇 陈紫君.过低LDL-C在动脉粥样硬化性心血管疾病中潜在风险循证学证据[J].心血管病学进展,2023,(11):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
Huang Cheng,Li Bo,Li Zhiyong,et al.The Evidence of the Potential Risk of Excessively Low Levels of LDL-C in ASCVD[J].Advances in Cardiovascular Diseases,2023,(9):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
[10]李开炜 彭汶婷 祝烨.降脂药物与认知功能下降的研究进展[J].心血管病学进展,2024,(3):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
LI Kaiwei,PENG Wenting,ZHU Ye.Lipid-Lowering Drugs and Cognitive Function Decline[J].Advances in Cardiovascular Diseases,2024,(9):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]